American Research Corporation at the Texas Liver Institue

San Antonio, Texas 78215

0 studies enrolling now · 2 studies all time

What they study most

Decompensated Cirrhosis, Fibrosis, Liver Diseases, Non-alcoholic Steatohepatitis

Studies at this site

• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis — Completed
• Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis — Status unconfirmed